Buchumschlag

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial site itself and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hübner, Hanna (VerfasserIn) , Kurbacher, Christian M. (VerfasserIn) , Kuesters, Geoffrey (VerfasserIn) , Hartkopf, Andreas D. (VerfasserIn) , Lux, Michael P. (VerfasserIn) , Huober, Jens (VerfasserIn) , Volz, Bernhard (VerfasserIn) , Taran, Florin-Andrei (VerfasserIn) , Overkamp, Friedrich (VerfasserIn) , Tesch, Hans (VerfasserIn) , Häberle, Lothar (VerfasserIn) , Lüftner, Diana (VerfasserIn) , Wallwiener, Markus (VerfasserIn) , Müller, Volkmar (VerfasserIn) , Beckmann, Matthias W. (VerfasserIn) , Belleville, Erik (VerfasserIn) , Ruebner, Matthias (VerfasserIn) , Untch, Michael (VerfasserIn) , Fasching, Peter Andreas (VerfasserIn) , Janni, Wolfgang (VerfasserIn) , Fehm, Tanja (VerfasserIn) , Kolberg, Hans-Christian (VerfasserIn) , Wallwiener, Diethelm (VerfasserIn) , Brucker, Sara Y. (VerfasserIn) , Schneeweiss, Andreas (VerfasserIn) , Ettl, Johannes (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 11 November 2020
In: BMC cancer
Year: 2020, Jahrgang: 20
ISSN:1471-2407
DOI:10.1186/s12885-020-07546-1
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12885-020-07546-1
Volltext
Verfasserangaben:Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss and Johannes Ettl
Beschreibung
Zusammenfassung:Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial site itself and is often a time-consuming procedure, which could result in missing out on potentially eligible patients. Pre-selection of those patients using a registry could facilitate the process of eligibility testing and increase the number of identified patients. One aim with the PRAEGNANT registry (NCT02338167) is to identify patients for therapies based on clinical and molecular data. Here, we report eligibility testing for the SHERBOC trial using the German PRAEGNANT registry.
Beschreibung:Gesehen am 08.02.2021
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-020-07546-1

Ähnliche Einträge